Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

NCT00800007 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: ANZ-521
DRUG: Placebo

Sponsor

Anza Therapeutics, Inc.